Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai...
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
NMPA Announces Pathway for Developing Generic Drugs Without Reference Preparation
The National Medical Products Administration (NMPA) has issued an announcement regarding the development of generic...
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...
Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment
China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...
China’s New Drug Quality Management Measures to Take Effect in 2024
The State Administration for Market Regulation (SAMR) has released the “Drug Operation and Use Quality...
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a...
Fujian’s Fourth Round VBP Seeks Public Feedback on Drug Procurement List
The Fujian drug and device joint procurement center has published the “Fujian Fourth Round Drug...
FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...
China Introduces Trial Measures for Science and Technology Ethics Review
The National Health Commission, Ministry of Science and Technology, Ministry of Education, and eight other...
Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...
China Releases First Supplement to 2020 Pharmacopoeia with 47 New Drug Varieties
The National Medical Products Administration (NMPA) and the National Health Commission have announced the release...
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement...
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...